Brought to you by 
Alimera Sciences raises $40mm through the sale of Series A preferred shares
26 Jul 2012
Executive Summary
Alimera Sciences Inc. (prescription ophthalmic drugs) has raised $40mm through the sale of Series A convertible preferred shares. The group of new and returning institutional investors--including Palo Alto Investors (lead), Sofinnova Ventures (it contributes a board member), and New Enterprise Associates--bought 1mm shares at $40 apiece and received warrants to buy another 300k shares at $44. Each Series A share converts into 13.75 common shares at $2.91. (The current market average is $2.96.) The proceeds will be used to continue developing and eventually market Iluvien for chronic diabetic macular edema. Iluvien has been approved in the EU and is in Phase II in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alimera Sciences raises $40mm through the sale of Series A preferred shares
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice